CLINICAL_TRIALS
trial_result
· 2020-12-21
Clinical Trial Update: Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease [Phase 3]
Summary
Phase 3 open-label extension study reporting long-term effects of migalastat HCL in Fabry disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-12-21